Loading...
NeuroSense Therapeutics Ltd.
NRSNW•NASDAQ
Healthcare
Biotechnology
$0.85
$0.07(8.97%)
NeuroSense Therapeutics Ltd. (NRSNW) Company Profile & Overview
Explore NeuroSense Therapeutics Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
NeuroSense Therapeutics Ltd. (NRSNW) Company Profile & Overview
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
SectorHealthcare
IndustryBiotechnology
CEOMr. Alon Ben-Noon
Contact Information
Company Facts
17 Employees
CountryIL
Actively Trading